2021
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaPatient-level factorsProvider-level factorsRenal cell carcinomaIndex dateRace/ethnicityInitial diagnosisCell carcinomaRisk ratioState cancer registry dataNumber of comorbiditiesMore comorbid conditionsPatient-level predictorsCancer registry dataProportion of daysProvider-level variablesPrescription drug filesMedian PDCMRCC diagnosisMRCC patientsPatient characteristicsPharmacy claimsComorbid conditionsMetastatic diagnosisMedical oncologyProvider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma
Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA. Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine 2021, 10: 6653-6665. PMID: 34480518, PMCID: PMC8495289, DOI: 10.1002/cam4.4201.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaPatient-level factorsRenal cell carcinomaCell carcinomaRisk ratioState cancer registry dataPatient-level predictorsPatient-level characteristicsCancer registry dataProvider Enumeration SystemMRCC diagnosisMedical oncologyInsurance typeMedicare patientsRegistry dataFemale providersPatientsMedian proportionPoisson regressionCare issuesPrivate insuranceMale providersAdherenceCarcinomaAnticancer agents
2017
4B.02 Increasing Survival in Stage IV NSCLC in Academic versus Community Based Centers in the National Cancer Database Topic: Medical Oncology
Ramalingam S, Dinan M, Crawford J. 4B.02 Increasing Survival in Stage IV NSCLC in Academic versus Community Based Centers in the National Cancer Database Topic: Medical Oncology. Journal Of Thoracic Oncology 2017, 12: s1560. DOI: 10.1016/j.jtho.2017.09.029.Peer-Reviewed Original ResearchTrends in hospital-physician integration in medical oncology.
Clough JD, Dinan MA, Schulman KA. Trends in hospital-physician integration in medical oncology. The American Journal Of Managed Care 2017, 23: 624-627. PMID: 29087634.Peer-Reviewed Original ResearchConceptsHospital outpatient departmentsMedical oncologyHigh-volume specialtiesOutpatient departmentMedical oncologistsMedical oncology practiceHospital-physician integrationProportion of physiciansGreater absolute changeManagement visitsThoracic surgeryOncology practiceRetrospective analysisOncologyAbsolute changeOncologistsMajority of evaluationsPhysiciansHigher proportionSpecialtiesDepartmentState-level variationYearsProportionSurgery
2016
PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress Topic: Medical Oncology
Kim E, Dinan M, Islam K, Fernandes A, Schwartzberg L, Croft E, Brahmer J, Mansfield A, Hyslop T, Burke L, Crawford J. PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress Topic: Medical Oncology. Journal Of Thoracic Oncology 2016, 11: s308-s309. DOI: 10.1016/j.jtho.2016.09.096.Peer-Reviewed Original Research